GlobeImmune Inc. received a milestone payment from Gilead Sciences Inc.
as a result of the biotechnology firms' 2011 collaboration agreement for
the development and commercialization of Tarmogen products, officials
Triggering the payment was the initiation of a Phase 2 clinical trial
for the investigation of the GS-4774 Tarmogen in patients with chronic
hepatitis B virus. GlobeImmune and Gilead's 2011 partnership centers on
the development and commercialization of Tarmogens for use in
conjunction with Viread — a Gilead drug — and other oral therapies for
the treatment of chronic HBV.
Labels: Gilead, Globeimmune, Tarmogen, Viread